Literature DB >> 4286381

Clinical and serological response to laboratory-acquired human infection by Indiana type vesicular stomatitis virus (VSV).

K M Johnson, J E Vogel, P H Peralta.   

Abstract

Entities:  

Mesh：

Year:  1966        PMID： 4286381     DOI： 10.4269/ajtmh.1966.15.244

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


× No keyword cloud information.
  41 in total

1.  Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo.

Authors:  James M Miller; Sarah McNulty Bidula; Troels Mygind Jensen; Carol Shoshkes Reiss
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2010-05-01

Review 2.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

3.  Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe.

Authors:  Selidji T Agnandji; Angela Huttner; Madeleine E Zinser; Patricia Njuguna; Christine Dahlke; José F Fernandes; Sabine Yerly; Julie-Anne Dayer; Verena Kraehling; Rahel Kasonta; Akim A Adegnika; Marcus Altfeld; Floriane Auderset; Emmanuel B Bache; Nadine Biedenkopf; Saskia Borregaard; Jessica S Brosnahan; Rebekah Burrow; Christophe Combescure; Jules Desmeules; Markus Eickmann; Sarah K Fehling; Axel Finckh; Ana Rita Goncalves; Martin P Grobusch; Jay Hooper; Alen Jambrecina; Anita L Kabwende; Gürkan Kaya; Domtila Kimani; Bertrand Lell; Barbara Lemaître; Ansgar W Lohse; Marguerite Massinga-Loembe; Alain Matthey; Benjamin Mordmüller; Anne Nolting; Caroline Ogwang; Michael Ramharter; Jonas Schmidt-Chanasit; Stefan Schmiedel; Peter Silvera; Felix R Stahl; Henry M Staines; Thomas Strecker; Hans C Stubbe; Benjamin Tsofa; Sherif Zaki; Patricia Fast; Vasee Moorthy; Laurent Kaiser; Sanjeev Krishna; Stephan Becker; Marie-Paule Kieny; Philip Bejon; Peter G Kremsner; Marylyn M Addo; Claire-Anne Siegrist
Journal:  N Engl J Med       Date:  2015-04-01       Impact factor: 91.245

Review 4.  Nonsegmented negative-strand viruses as vaccine vectors.

Authors:  Alexander Bukreyev; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2006-11       Impact factor: 5.103

5.  Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge.

Authors:  Farooq Nasar; Demetrius Matassov; Robert L Seymour; Theresa Latham; Rodion V Gorchakov; Rebecca M Nowak; Grace Leal; Stefan Hamm; John H Eldridge; Robert B Tesh; David K Clarke; Scott C Weaver
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

6.  Toll-like receptor signaling controls reactivation of KSHV from latency.

Authors:  Sean M Gregory; John A West; Patrick J Dillon; Chelsey Hilscher; Dirk P Dittmer; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-29       Impact factor: 11.205

7.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 8.  Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Authors:  Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

Review 9.  From bench to almost bedside: the long road to a licensed Ebola virus vaccine.

Authors:  Gary Wong; Emelissa J Mendoza; Francis A Plummer; George F Gao; Gary P Kobinger; Xiangguo Qiu
Journal:  Expert Opin Biol Ther       Date:  2017-11-17       Impact factor: 4.388

10.  In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation.

Authors:  J Erik Johnson; John W Coleman; Narender K Kalyan; Priscilla Calderon; Kevin J Wright; Jennifer Obregon; Eleanor Ogin-Wilson; Robert J Natuk; David K Clarke; Stephen A Udem; David Cooper; R Michael Hendry
Journal:  Vaccine       Date:  2009-03-13       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.